UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 319, 2018 Rafina Innovations Inc. Exact name of registrant as specified in its charter

Nevada	000-53089	30-0428006
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Kintyre House, 209 Govan Road, Glasgow, Scotland	G51 1 HJ
(Address of principal executive offices)	(Zip Code)

+44 141 3700321

Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

SECTION 3. SECURITIES AND TRADING MARKETS

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

On October 19, 2018 the Company's Board of Directors approved the grant of a total of 1,500,000 stock awards which vested on the date of grant, and a total of 1,500,000 directors' stock options at $0.70 per share which vest on grant date each year for a total of five (5) years from the original date of grant.

Details of the award and option grants are provided below:

Name	Position	Number of stock awards, vesting on date of grant
Mr. Constantinos Zertalis	CEO, President and Director	600,000
Mr. Georgios Thrapsaniotis	Treasurer and Director	200,000
Ms. Paraskevi Pylarinou	CFO, Secretary and Director	200,000
Mr. Yiannis Levantis	Director	500,000
Total awards granted		1,500,000

Name	Position	Number of stock options for exercise at $0.70 per share granted each year for Five (5) years, vesting on grant date and expiring five years from vesting date.
Mr. Constantinos Zertalis	CEO, President and Director	500,000
Mr. Georgios Thrapsaniotis	Treasurer and Director	300,000
Ms. Paraskevi Pylarinou	CFO, Secretary and Director	300,000
Mr. Yiannis Levantis	Director	400,000
Total options granted per year		1,500,000

A copy of each of the form of Stock award and Stock Option Grant Notice is filed as Exhibit 10.1 to this Current Report on Form 8-K.

Exemption From Registration. The shares of Common Stock referenced herein were issued in reliance upon the exemption from securities registration afforded by the provisions of Regulation S of the Securities Act of 1933, as amended, ("Securities Act"), as promulgated by the U.S. Securities and Exchange Commission under the Securities Act. Our reliance upon the exemption under Rule 903 of Regulation S of the Securities Act was based on the fact that the sales of the securities were completed in an "offshore transaction", as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. The investor was not a US person, as defined in Regulation S, and was not acquiring the securities for the account or benefit of a US person.

SECTION 5. CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

~~Departure of Directors or Certain Officers;~~ Election of Directors~~; Appointment of Certain Officers~~

~~Effective~~Appointment ~~October 3, 2018, Dr Christos Kapatos resigned from his position as Director~~ of ~~the Company. The written resignation of Dr. Kapatos is appended to this Current Report on Form 8-K as exhibit 10.1.~~Chairman

~~Effective~~On October 319, 2018, ~~Mr.~~the ~~Sotirios~~Company's ~~Leontaritis~~Board ~~resigned~~of ~~from~~Directors ~~his~~appointed ~~position~~Mr. asConstantinos ~~the~~Zertalis, ~~President~~CEO, ~~Director~~President and ~~Chief~~Director ~~Financial~~as ~~Officer~~Chairman of the ~~Company.~~Board ~~Mr. Leontaritis' resignation was not the result~~ of ~~any disagreement with the Corporation regarding operations, policies, practices or otherwise~~Directors.

Effective October 3, 2018, Mr Nikolaos Kardaras resigned from his position as the Secretary and Director of the Company. Mr. Kardaras' resignation was not the result of any disagreement with the Corporation regarding operations, policies, practices or otherwise. Mr. Kardaras will continue to consult for the Company as an independent contractor in his capacity as in-house legal counsel.2

~~Concurrent~~Resignation ~~with the aforementioned resignations, the Board~~ of Directors appointed Mr. Constantinos Zertalis ("Zertalis") as a member of the Board of Directors and the President of the Company and Miss Paraskevi Pylarinou ("Pylarinou") as a member of the Board of Directors, Secretary and CFO of the Company.Officers

~~Mr.~~On ~~Zertalis~~November ~~is a controlling shareholder of the Company holding 6~~21,~~227,030~~ ~~shares~~2018 of the Company's ~~common~~Chief ~~stock~~Technology ~~representing~~Officer, ~~approximately 43~~Dr.~~21%of~~ ~~the~~Christos ~~issued~~Kapatos ~~and~~resigned ~~outstanding~~his ~~shares.~~position Mras ~~Zertalis,~~Chief ~~age~~Technology ~~41,~~Officer ~~received~~and as a ~~BBA~~consultant indue ~~Management~~to ~~and Finance from~~ the ~~Bernard~~Company's ~~Baruch~~breach ~~College (CUNY)~~ of ~~New~~Sections ~~York~~3.1 ~~in 2003~~ and an3.2 ~~Executive~~of ~~Master's~~that incertain ~~public~~Consulting ~~Affairs~~Agreement ~~and~~originally ~~Administration~~entered ininto ~~International~~April ~~Economic~~16, ~~Policy~~2014 ~~and~~(as ~~Advance~~amended ~~Management~~ from ~~Columbia~~time ~~University~~to oftime, ~~New~~including, ~~York~~without inlimitation, ~~2005.~~Addendum ~~Since~~1, ~~2013~~Addendum ~~Mr.~~2 ~~Zertalis~~and ~~has~~Addendum ~~served~~3, ascollectively, ~~Europe~~the ~~Retail~~"Consulting ~~Director~~Agreement"), all of ~~Ria~~which ~~Money~~agreements ~~Transfer~~have –been ~~Euronet~~previously ~~Worldwide~~filed inwith ~~Madrid, Spain, responsible for~~ the ~~strategic~~Securities ~~operation~~and ~~planning~~Exchange ~~process~~Commission ~~and~~on ~~since~~Current ~~2008~~Report ~~has~~on ~~served~~Form as8-K. The ~~Chief~~Company ~~Executive~~declined ~~Officer~~to ofcure ~~Zertalis~~the ~~Group~~noticed breach(es) in ~~Nicosia,~~the ~~Cyprus.~~ten He(10) ~~also~~day ~~served~~period as ~~Operations~~allotted ~~Manager~~from ofnotice ~~Hellenic~~date ~~Tzilalis Ltd in Nicosia, Cyprus~~ and ~~since~~subsequently ~~2001~~accepted ~~and~~the ~~for~~resignation ~~four~~of ~~years~~Dr. heKapatos ~~served~~effective asNovember ~~Assistant~~21, ~~Chief~~2018. Further, ~~Operating~~on ~~Officer~~December in4, 2018 the ~~Department~~Company ~~for~~notified ~~General~~Dr. ~~Assembly~~Kapatos ~~and~~of ~~Conference~~the ~~Management~~termination of ~~United~~that ~~Nations~~certain ~~Headquarters~~Acquisition inagreement ~~New~~between ~~York, U~~Dr.~~S.A.~~ ~~The~~Kapatos ~~Company~~and ~~believes~~HCI ~~that~~VIOCARE ~~Mr.~~TECHNOLOGIES ~~Zertalis~~LIMITED, ~~will~~the beCompany's awholly ~~valuable~~owned ~~addition~~subsidiary, todated ~~the~~April ~~team~~16, 2014, as weamended ~~continue~~May ~~to develop our business strategy~~8, ~~strengthen~~2015 ~~our~~(collectively ~~position in~~ the ~~global~~"Acquisition ~~market and increase corporate visibility~~Agreement").

~~Mr.~~Until ~~Zertalis~~such istime ~~not~~as ana ~~officer~~new orChief ~~director~~Technology ofOfficer ~~any~~is ~~other~~appointed ~~reporting issuers~~Dr. ~~Other~~Hari ~~than~~Elangovan, asan ~~set~~employee ~~out~~of ~~above~~the Company since 2014, ~~Mr.~~will ~~Zertalis~~be ~~does~~assuming ~~not~~a ~~currently~~leadership ~~hold~~role ~~other~~in ~~positions~~the ~~with~~ongoing development of the Company's technology. Dr. MrElangovan ~~Zertalis~~began ~~does~~his ~~not~~career ~~have~~as a ~~family~~medical ~~relationship~~doctor, ~~with~~having ~~any~~graduated ~~other~~in ~~executive~~Chennai, ~~officers~~India orwith ~~directors~~a ofmedical ~~the~~degree ~~Company~~(M.B.B.S.) orof ~~persons~~First ~~nominated~~Class orDistinction. Dr. ~~chosen~~Elangovan bydecided ~~the~~to ~~Company~~transition to ~~become~~the ~~directors~~field orof ~~executive~~technology ~~officers.~~starting ~~There~~2011 and isearned noa ~~material~~Biomedical ~~plan~~Engineering PhD, ~~contract~~as orthe ~~arrangement~~University ~~(whether~~of orStrathclyde, ~~not~~which ~~written)~~he tocompleted ~~which~~with Mrhigh accolades. Dr. ~~Zertalis~~Elangovan ishas aan ~~party~~impressive ortrack record in ~~which~~Biomedical heEngineering ~~participates~~R&D, ~~that~~with isa ~~entered~~significant ~~into~~number orof ~~material~~patents ~~amendment~~to inhis ~~connection~~name, ~~with~~as ~~the~~Chief ~~Company's~~Inventor. ~~appointment~~Some of ~~Constantinos~~these ~~Zertalis,~~include ormicro-robotics ~~any~~technologies ~~grant~~for ormicro-surgery, ~~award~~sensor totechnologies ~~him~~for orcar ~~modification~~bump ~~thereto~~recognition, ~~under~~respiratory ~~any~~assist ~~such~~devices ~~plan,~~for ~~contract~~sleep orapnoea, ~~arrangement~~intelligent inmedical ~~connection~~mattress ~~with~~technologies, ~~the Company's appointment of Mr. Zertalis~~ to ~~the~~name ~~Board~~a ~~of Directors~~few.

~~Miss~~SECTION Pylarinou, age 30, received a Bachelor's Degree in Public Policy and Strategic Planning from the Panteion University of Athens, Greece in 2010 and a Master in Business Administration of Piraeus University, Section of Executive Management and Business Administration (EMBA) of Piraeus, Greece, in 20178. FINANCIAL ~~Miss~~STATEMENTS ~~Pylarinou~~AND has work experience in the financial sector of corporations, including Attico Medical Center S.A. in Athens, Greece and Dalmar Group of Companies – DAREX S.A. During 2016, Miss Pylarinou served as Financial Analyst of of the Company, and since 2017 she serves as Financial Controller and Reporting Analyst of the Company. The Company believes that Miss Pylarinou will be a valuable addition to the team.EXHIBITS

~~Miss.~~ITEM ~~Pylarinou is not an officer or director of any other reporting issuers~~8.01 OTHER Other than as set out above, Miss. Pylarinou does not currently hold other positions with the Company. Miss. Pylarinou does not have a family relationship with any other executive officers or directors of the Company or persons nominated or chosen by the Company to become directors or executive officers. There is no material plan, contract or arrangement (whether or not written) to which Miss. Pylarinou is a party or in which she participates that is entered into or material amendment in connection with the Company's appointment of Miss. Pylarinou, or any grant or award to her or modification thereto, under any such plan, contract or arrangement in connection with the Company's appointment of Miss. Pylarinou to the Board of Directors.EVENTS

~~Furthermore~~The Company's Board of Directors have determined to hold an Annual General Meeting of Shareholders (the "Meeting") under the appropriate Nevada Statutes and applicable SEC rules, at the ~~Company~~first ispracticable ~~not~~date. The ~~aware~~formal business of ~~any~~this ~~transaction~~Meeting ~~requiring~~will ~~disclosure~~include ~~under~~the ~~Item~~election ~~404(~~of directors, with the informal business to include a) ofcorporate ~~Regulation~~update ~~S-K~~from the Company's CEO and a set period for questions and answers from the floor.

The Company intends to publish the associated materials with respect to the Meeting in the coming weeks.

SECTION 9. FINANCIAL STATEMENTS AND EXHIBITS

9.01 Financial Statements and Exhibits

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K:

Exhibit No.	Description
Exhibit no.		Description
10.1	~~Letter of Resignation, Dr. Christos Kapatos~~	~~Filed~~Form ~~herewith~~of Stock Award and Stock Option Grant Notices	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Rafina Innovations Inc.
Dated: October 25, 2018	By:	/s/ Constantinos Zertalis
Date: December 20, 2018	By:	/s/ Constantinos Zertalis
	Name:	Constantinos Zertalis
		Name: Constantinos Zertalis
	Title:	President and Director
		Title: President, CEO, and Director

Filing Compare · Rafina Innovations Inc.